RICARDO
RUIZ VILLAVERDE
Hospital Universitari Germans Trias i Pujol
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitari Germans Trias i Pujol (22)
2024
-
Real-world Safety and Efficacy of Risankizumab in Psoriatic Patients: A Multicenter, Retrospective, and Not-interventional Study
Actas Dermo-Sifiliograficas
-
[Translated article] Requirements for Accessing New Dermatology Drugs in Spain: Results of the EQUIDAD Study
Actas Dermo-Sifiliograficas, Vol. 115, Núm. 3, pp. T237-T245
2023
-
Drug Survival in Cyclosporine Treatment for Moderate to Severe Atopic Dermatitis: Analysis of the Spanish Atopic Dermatitis Registry (BIOBADATOP)
Actas Dermo-Sifiliograficas
-
Effectiveness and safety of brodalumab in the treatment of plaque, scalp and palmoplantar psoriasis: A multicentre retrospective study in a Spanish population
Australasian Journal of Dermatology, Vol. 64, Núm. 4, pp. e317-e326
-
Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group
Journal of the European Academy of Dermatology and Venereology, Vol. 37, Núm. 12, pp. 2517-2525
-
Pharmacogenetic biomarkers for secukinumab response in psoriasis patients in real-life clinical practice
Journal of the European Academy of Dermatology and Venereology
-
Predictive factors for anti-MDA5 antibody in patients with dermatomyositis: a retrospective multicenter study
JDDG - Journal of the German Society of Dermatology, Vol. 21, Núm. 7, pp. 741-748
-
Prädiktive Faktoren für Anti-MDA5-Antikörper bei Patienten mit Dermatomyositis: eine retrospektive multizentrische Studie
JDDG - Journal of the German Society of Dermatology, Vol. 21, Núm. 7, pp. 741-750
-
Requirements for Accessing New Dermatology Drugs in Spain: Results of the EQUIDAD Study
Actas Dermo-Sifiliograficas
-
Treatment of severe atopic dermatitis with tralokinumab in clinical practice: short-term effectiveness and safety results
Clinical and experimental dermatology, Vol. 48, Núm. 9, pp. 991-997
-
Updated Review on Treatment of Atopic Dermatitis
Journal of Investigational Allergology and Clinical Immunology, Vol. 33, Núm. 3, pp. 158-167
-
[Translated article] Updated Position of the Spanish Psoriasis Group (GPs) on the Use of Biosimilar Drugs in Moderate to Severe Psoriasis
Actas Dermo-Sifiliograficas, Vol. 114, Núm. 6, pp. T494-T501
2022
-
Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group
Dermatologic Therapy, Vol. 35, Núm. 2
-
Survival of guselkumab therapy in moderate to severe plaque psoriasis at 52 weeks in a real-world clinical setting: observational, retrospective, multi-centre study by the Spanish Psoriasis Group
Journal of Dermatological Treatment
2021
-
A new classification of the severity of psoriasis: What’s moderate psoriasis?
Life, Vol. 11, Núm. 7
-
Management of Psoriasis During Preconception, Pregnancy, Postpartum, and Breastfeeding: A Consensus Statement
Actas Dermo-Sifiliograficas, Vol. 112, Núm. 3, pp. 225-241
2020
-
Maculopapular eruptions associated to COVID-19: A subanalysis of the COVID-Piel study
Dermatologic Therapy, Vol. 33, Núm. 6
-
Real-world effectiveness and safety of apremilast in psoriasis at 52 weeks: a retrospective, observational, multicentre study by the Spanish Psoriasis Group
Journal of the European Academy of Dermatology and Venereology, Vol. 34, Núm. 12, pp. 2821-2829
-
The effectiveness and safety of ixekizumab in psoriasis patients under clinical practice conditions: A Spanish multicentre retrospective study
Dermatologic Therapy, Vol. 33, Núm. 6
2018
-
Redefining the therapeutic objective in psoriatic patients candidates for biological therapy
Journal of Dermatological Treatment, Vol. 29, Núm. 4, pp. 334-346